NFV NEWS

TMCNet:  Kyowa Hakko Kirin's Nouriast for Parkinson's Disease - Forecast and Market Analysis to 2022

[May 19, 2014]

Kyowa Hakko Kirin's Nouriast for Parkinson's Disease - Forecast and Market Analysis to 2022

(M2 PressWIRE Via Acquire Media NewsEdge) Dublin - Research and Markets (http://www.researchandmarkets.com/research/x57b5l/nouriast) has announced the addition of the "Nouriast (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering.


Istradefylline is a first-in-class adenosine A2 receptor inhibitor, marketed in Japan under the brand name Nouriast by Kyowa Hakko Kirin. It was approved in Japan for adjunct use with levodopa in advanced-stage patients with wearing-off in March 2013, and launched in May 2013 (Kyowa Hakko Kirin, press release, March 25, 2013; Kyowa Hakko Kirin, press release, May 29, 2013).

Scope - Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Nouriast including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Nouriast for the top seven countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Nouriast (istradefylline) 7 Appendix For more information visit http://www.researchandmarkets.com/research/x57b5l/nouriast CONTACT: Research and Markets, Laura Wood, Senior Manager.

press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Central Nervous System (http://www.researchandmarkets.com/categories.asp?cat_id=117&campaign_id=x57b5l) .

(c) 2014 M2 COMMUNICATIONS

[ Back To NFVZone's Homepage ]